ASCO 2014 – Immuno-Oncology

Phase 2 Trial of Nivolumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology

Pidilizumab in Relapsed Metastatic Melanoma

ASCO 2014 – Immuno-Oncology

Nivolumab and Erlotinib in EGFR-Mutation Positive Treatment-Resistant Advanced NSCLC

ASCO 2014 – Immuno-Oncology

Nivolumab in Chemotherapy-Naïve Advanced NSCLC

ASCO 2014 – Immuno-Oncology

Blinatumomab in Relapsed/Refractory Acute Lymphoblastic Leukemia

ASCO 2014 – Immuno-Oncology

Adoptive T-Cell Therapy for Cervical Cancer

ASCO 2014 – Immuno-Oncology

Pembrolizumab (MK-3745) in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology

Concurrent Treatment of Advanced Melanoma with Ipilimumab and Nivolumab

ASCO 2014 – Immuno-Oncology

Ipilimumab for Initial Treatment of Metastatic Uveal Melanoma

ASCO 2014 – Immuno-Oncology

Nivolumab Combined with Ipilimumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology

Page 2 of 3

1
2
3